Search Results

Displaying Results 101-125 of 294 "'INT'"

Mar 17, 2026, 09:00 ET Philips Sonicare declares World Oral Health Night, spotlighting what manual brushing leaves behind

because it is the gateway to overall health. Want to explore the full range of Philips Sonicare products? Visit Philips.com.1 Slot DE et al, Int Dent Hygiene (2012): 187-972 Philips Sonicare Diamond Clean range + A3 brush head, in hard-to-reach areas vs. a manual toothbrush in

More news about: Philips Sonicare


Mar 16, 2026, 16:33 ET Qubrid AI Accelerates Open-Source Model Inferencing with NVIDIA AI Infrastructure and One Single API for Enterprise Agents

optimization using TensorRT,- NVIDIA's high-performance inference SDK built on CUDA. TensorRT compiles and optimizes models through precision tuning (FP16 and INT8), layer fusion, and kernel auto-optimization. For large language models, we apply

More news about: Qubrid, Inc


Mar 13, 2026, 10:00 ET clinicasdelhombre.com abre nueva clínica en Iztapalapa para acercar atención médica especializada a más hombres de la Ciudad de México

Ubicada en Calzada de la Viga 1174, Int. 904, Colonia El Triunfo, esta clínica fue pensada para facilitar el acceso a hombres que viven o trabajan en el oriente de la Ciudad de México y

More news about: elery.co


Mar 12, 2026, 07:30 ET Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study

still seek full approval using event-free survival as an endpoint.About INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.

More news about: Intensity Therapeutics Inc.


Mar 10, 2026, 19:30 ET Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD™ 2026 Annual Meeting

doi:10.1038/s41467-021-23507-z.2. Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.

More news about: Eisai Inc.


Mar 06, 2026, 07:47 ET Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

www.intensitytherapeutics.com.  About INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.

More news about: Intensity Therapeutics Inc.


Mar 05, 2026, 13:03 ET Neuspera Medical Announces 12-Month Pivotal Trial Results for the Company's Integrated Sacral Neuromodulation System for Urinary Urge Incontinence

45(S1), S7-S219.Bretschneider CE, et al. "Device-Related Reoperations 8 Years Following Sacral Neuromodulation Implantation in Older Women". Int Urogynecol J. 2024 Dec;35(12):2349-2355.Padron, Osvaldo, et al. "MP30-12 Results of the SANS-UUI, Phase II Study: Safety Outcomes at 6-Months

More news about: Neuspera Medical


Mar 05, 2026, 07:47 ET GFT Technologies Recognized as the Most Valuable Pioneer in QKS Group's AI Maturity Matrix™ for Digital Banking Transformation Services, 2026

https://www.gft.com/int/en/about-us/recognitions/ai-maturity-matrix-digital-banking-transformation-servicesAbout GFT TechnologiesGFT Technologies is a responsible AI-centric global

More news about: QKS Group


Mar 05, 2026, 06:00 ET B/CORE Acquires Fuel Consulting to Deepen Mission Reach Across the Intelligence Community

GeoYeti, teKnoluxion, 2Twelve Solutions, and Fuel Consulting, with capabilities spanning AI/ML, data engineering, DevSecOps, secure hybrid cloud, and multi-INT analytics. The company is headquartered in Reston, Virginia. B/CORE is a NewSpring Holdings platform company. For more information, visit bcore.com.About

More news about: Bcore


Mar 04, 2026, 18:08 ET TECNO Advances Mobile Creativity and On-Device Generative AI at MWC 2026 with Arm Collaboration

Concept Technology leverages advanced Armv9 CPU capabilities, seamlessly accessed through Arm Kleidi™AI. By leveraging the Armv9 CPU's specialized i8MM (Int8 Matrix Multiplication) instructions through KleidiAI, the collaboration accelerates core machine learning (ML) operations across mainstream frameworks.

More news about: TECNO


Mar 04, 2026, 13:40 ET Axi lanza Buy Crypto para simplificar la inversión en activos digitales

https://www.axi.com/int/blog/education/cryptocurrencies/spot-trading-cryptocurrencyAcerca de AxiAxi es una marca mundial de operaciones en línea de FX y CFD, que atiende

More news about: AxiTrader


Mar 04, 2026, 13:33 ET Axi inaugura a compra de criptomoedas para simplificar o investimento em ativos digitais

https://www.axi.com/int/blog/education/cryptocurrencies/spot-trading-cryptocurrencySobre a AxiA Axi é uma marca global de trading de FX e CFD online, atendendo milhares

More news about: AxiTrader


Mar 04, 2026, 10:31 ET Axi startet Buy Crypto zur Vereinfachung von Investitionen in digitale Vermögenswerte

https://www.axi.com/int/blog/education/cryptocurrencies/spot-trading-cryptocurrencyInformationen zu AxiAxi ist eine globale Online-FX- und CFD-Handelsmarke, die Tausende

More news about: AxiTrader


Mar 04, 2026, 10:26 ET Axi lance Buy Crypto pour simplifier l'investissement dans les actifs numériques

https://www.axi.com/int/blog/education/cryptocurrencies/spot-trading-cryptocurrencyÀ propos d'AxiAxi est une marque mondiale de trading en ligne pour les devises et les

More news about: AxiTrader


Mar 04, 2026, 06:02 ET Axi lanza Buy Crypto para simplificar la inversión en activos digitales

https://www.axi.com/int/blog/education/cryptocurrencies/spot-trading-cryptocurrencyAcerca de AxiAxi es una plataforma global de trading de divisas y CFD en línea que atiende

More news about: AxiTrader


Mar 04, 2026, 05:00 ET Axi Launches Buy Crypto to Simplify Digital Asset Investing

https://www.axi.com/int/blog/education/cryptocurrencies/spot-trading-cryptocurrencyAbout AxiAxi is a global online FX and CFD trading brand, serving thousands

More news about: AxiTrader


Mar 04, 2026, 05:00 ET Axi Launches Buy Crypto to Simplify Digital Asset Investing

https://www.axi.com/int/blog/education/cryptocurrencies/spot-trading-cryptocurrencyAbout AxiAxi is a global online FX and CFD trading brand, serving thousands of customers

More news about: AxiTrader


Mar 03, 2026, 09:48 ET New Research Finds Peanut Butter Consumption Builds Muscle Power in Older Adults

The effects of resistance training with or without peanut protein supplementation on skeletal muscle and strength adaptations in older individuals. J Int Soc Sports Nutr. 2020 Dec 14;17(1):66. doi: 10.1186/s12970-020-00397-y. PMID: 33317565; PMCID: PMC7734909.Plotkin DL, Delcastillo K, Van Every

More news about: The Peanut Institute


Feb 26, 2026, 08:48 ET FuriosaAI and Helikai Partner to Deliver Secure, Production-Ready Enterprise AI Automation Stack

domain–specific expertise, deterministic behavior, and immediate ROI.By running Helibots on Furiosa's RNGD hardware — which delivers 512 TOPS of INT8 compute at just 180W — organizations can deploy complex agentic workflows in environments where traditional GPU–based systems are impractical due to

More news about: Helikai, Inc.


Feb 25, 2026, 13:02 ET Die an der Euronext Amsterdam notierte SWI Stoneweg Icona Group steigt mit einer Mehrheitsbeteiligung an Polarise, einem führenden europäischen NVIDIA Cloud Partner, in den Bereich KI-Computing ein und schafft eine vollständig integrierte europäische KI-Infrastrukturplattform

ner-mehrheitsbeteiligung-an-polarise-einem-fuhrenden-europaischen-nvidia-cloud-partner-in-den-bereich-ki-computing-ein-und-schafft-eine-vollstandig-int-302697366.html

More news about: SWI Group


Feb 24, 2026, 09:00 ET Royal Biologics Announces Strategic Partnership with Jellagen (UK) to Bring Jellyfish-Derived Collagen Type Zero to the U.S. Regenerative Medicine Market

et al. In Vivo Analysis of the Biocompatibility and Immune Response of Jellyfish Collagen Scaffolds and its Suitability for Bone Regeneration. Int J Mol Sci. 2020 Jun 25;21(12):4518.Bowen A.J, et al.  Larynx proteomics after jellyfish collagen IL: Increased ECM/collagen and suppressed

More news about: Royal Biologics


Feb 17, 2026, 07:00 ET Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis

Faustman DL, Davis M, Kuhtreiber WM. TNFR2 Agonism: Basic Science and Promising Treatment for Multiple Sclerosis and Related Diseases. Int J Mol Sci. 2025 Aug 14;26(16):7839. doi: 10.3390/ijms26167839. PMID: 40869160; PMCID: PMC12386426.

More news about: Nektar Therapeutics


Feb 13, 2026, 18:01 ET Breakthrough Study Confirms HYD LLC's 30-Year Research on Deuterium Modulation in Cancer Gene Expression

(Csonka, G.I.; Papp, A.; Somlyai, I.; Somlyai, G. Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in Deuterium Concentration. Int. J. Mol. Sci. 2025, 26, 10969. https://doi.org/10.3390/ijms262210969)

More news about: HYD LLC


Feb 13, 2026, 08:58 ET Intensity Therapeutics Announces Reverse Stock Split

any payments in cash in lieu of fractional shares, if applicable.About INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.

More news about: Intensity Therapeutics Inc.


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.